Reviva Pharmaceuticals Holdings Inc.
RVPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.13M
Close$
Compare to Similar Companies
| P/E Ratio | Dividends | Return on Equity | Price-to-Sales | Debt-to-Equity | ||
|---|---|---|---|---|---|---|
| Reviva Pharmaceuticals Holdings Inc. | -0.1 | - | -113901094% | - | - | |
$0.39
28.7% downside
Current Fair Value
28.7% downsideOvervalued by 28.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.13 Million |
|---|---|
| Enterprise Value | $-13,830,523.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.48 |
| Beta | 0.47 |
| Outstanding Shares | 7,022,945 |
Return
| Return on Equity | -113901093.61% |
|---|---|
| Return on Assets | -84317510.63% |
| Return on Invested Capital | -115822674.00% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | 0.13 |
| Price to Sales | - |
| Price to Book Ratio | 0.28 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 5.08% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 52.49% |
|---|---|
| Total Invested | $1▼ 100.00% |
| Investors Holding | 1▼ 36.00% |
ESG Score
No data
About Reviva Pharmaceuticals Holdings Inc.
5 employeesReviva Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary ...